Last 48 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
ResMed Inc.'s quarterly P/E stands at 20.7x, down 8.2% year-over-year. EV/EBITDA has compressed 6.3% YoY to 16.1x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 21.76 | 20.71 | 22.47 | 28.87 | 25.00 | 22.57 | 24.43 | 28.92 | 24.17 | 24.27 | 30.29 | 24.81 | 35.02 |
| — | -8.2% | -8.0% | -0.2% | +3.4% | -7.0% | -19.3% | +16.6% | -31.0% | -30.0% | -10.9% | -35.0% | -11.1% | |
| P/S Ratio | 5.86 | 5.76 | 6.22 | 7.53 | 7.04 | 6.38 | 6.58 | 7.36 | 5.77 | 6.10 | 5.46 | 4.95 | 7.18 |
| — | -9.6% | -5.5% | +2.4% | +21.9% | +4.6% | +20.6% | +48.7% | -19.6% | -15.6% | -26.5% | -41.5% | -14.7% | |
| P/B Ratio | 5.11 | 5.08 | 5.60 | 6.58 | 6.36 | 5.94 | 6.43 | 6.94 | 5.81 | 6.31 | 5.66 | 5.13 | 7.81 |
| — | -14.4% | -12.8% | -5.2% | +9.5% | -5.8% | +13.5% | +35.2% | -25.6% | -23.2% | -31.0% | -45.2% | -14.9% | |
| P/FCF | 18.14 | 15.85 | 28.45 | 24.28 | 18.66 | 14.85 | 29.12 | 29.44 | 17.06 | 19.26 | 25.43 | 22.22 | 40.56 |
| — | +6.8% | -2.3% | -17.5% | +9.4% | -22.9% | +14.5% | +32.5% | -57.9% | -40.0% | -67.8% | -96.6% | -75.2% | |
| EV / EBITDA | 15.51 | 16.10 | 15.63 | 20.09 | 17.76 | 17.18 | 18.00 | 20.67 | 16.56 | 17.55 | 21.22 | 16.86 | 25.41 |
| — | -6.3% | -13.2% | -2.8% | +7.3% | -2.1% | -15.2% | +22.6% | -34.8% | -26.5% | -14.6% | -34.3% | -2.9% | |
| EV / EBIT | 17.68 | 16.10 | 17.36 | 21.79 | 20.51 | 19.67 | 20.13 | 23.43 | 23.47 | 20.11 | 19.57 | 19.98 | 29.34 |
| — | -18.1% | -13.8% | -7.0% | -12.6% | -2.2% | +2.9% | +17.3% | -20.0% | -28.4% | -30.2% | -32.9% | -4.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
ResMed Inc.'s operating margin was 34.9% in Q3 2026, down 0.1 pp QoQ and up 1.9 pp YoY. Gross margin expanded 4.9% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.4% | 62.2% | 62.2% | 61.5% | 60.8% | 59.3% | 58.6% | 58.6% | 57.6% | 56.9% | 57.6% | 54.4% | 55.0% |
| — | +4.9% | +6.1% | +4.9% | +5.7% | +4.2% | +1.8% | +7.6% | +4.6% | +3.0% | +2.7% | -4.3% | -3.7% | |
| Operating Margin | 32.7% | 34.9% | 35.0% | 33.4% | 33.7% | 33.0% | 32.5% | 31.6% | 31.2% | 31.3% | 23.7% | 26.2% | 24.5% |
| — | +5.8% | +7.5% | +5.7% | +8.2% | +5.4% | +37.6% | +20.6% | +27.0% | +16.2% | -12.7% | -9.6% | -12.1% | |
| Net Margin | 27.2% | 27.9% | 27.6% | 26.1% | 28.2% | 28.3% | 26.9% | 25.4% | 23.9% | 25.1% | 18.0% | 19.9% | 20.5% |
| — | -1.4% | +2.7% | +2.6% | +17.9% | +12.6% | +49.7% | +27.7% | +16.7% | +20.6% | -17.5% | -10.1% | -4.0% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 25.9% | 6.2% | 6.3% | 5.8% | 6.6% | 6.8% | 6.6% | 6.2% | 6.2% | 6.6% | 4.8% | 5.2% | 5.7% |
| — | -7.9% | -4.3% | -6.9% | +7.1% | +2.5% | +37.9% | +18.2% | +8.1% | +8.8% | -23.8% | -15.5% | -3.0% | |
| ROA | 18.6% | 4.6% | 4.7% | 4.2% | 4.8% | 5.0% | 4.8% | 4.4% | 4.3% | 4.4% | 3.1% | 3.3% | 3.4% |
| — | -7.1% | -2.7% | -4.3% | +13.0% | +13.3% | +56.8% | +35.8% | +25.2% | +26.1% | -19.4% | -20.6% | -12.6% | |
| ROIC | 22.8% | 6.5% | 6.5% | 6.0% | 6.2% | 5.8% | 5.6% | 5.2% | 5.2% | 5.0% | 3.7% | 3.9% | 3.8% |
| — | +11.6% | +16.1% | +14.5% | +19.2% | +15.8% | +51.8% | +32.8% | +36.6% | +20.5% | -16.0% | -22.4% | -21.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
ResMed Inc.'s Debt/EBITDA ratio is 1.7x, down from 1.8x last quarter — comfortably within a safe range. The current ratio has weakened 11.8% YoY to 3.01x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.14 | 0.13 | 0.16 | 0.14 | 0.14 | 0.15 | 0.16 | 0.16 | 0.18 | 0.25 | 0.31 | 0.35 | 0.38 |
| — | -14.2% | -0.9% | -15.5% | -20.6% | -40.0% | -48.5% | -53.5% | -53.0% | -42.5% | -40.2% | +29.8% | +40.1% | |
| Debt / EBITDA | 0.44 | 1.69 | 1.79 | 1.71 | 1.61 | 1.76 | 1.77 | 1.93 | 2.00 | 2.72 | 4.45 | 4.37 | 4.78 |
| — | -3.9% | +0.8% | -11.2% | -19.6% | -35.4% | -60.1% | -55.9% | -58.1% | -44.2% | -25.3% | +50.1% | +56.5% | |
| Current Ratio | 3.44 | 3.01 | 3.06 | 2.89 | 3.44 | 3.41 | 3.33 | 2.92 | 2.59 | 3.04 | 3.11 | 2.99 | 3.12 |
| — | -11.8% | -8.1% | -1.1% | +32.9% | +12.2% | +7.0% | -2.3% | -17.1% | -0.9% | -1.9% | +1.8% | +11.4% | |
| Quick Ratio | 2.53 | 2.33 | 2.32 | 2.13 | 2.53 | 2.49 | 2.29 | 1.91 | 1.69 | 1.97 | 1.63 | 1.75 | 1.81 |
| — | -6.5% | +1.2% | +12.0% | +50.0% | +26.7% | +40.4% | +9.1% | -6.6% | +13.0% | -10.4% | +3.5% | +4.8% | |
| Interest Coverage | 133.05 | 40.68 | 63.42 | 51.81 | — | 131.23 | 88.37 | 70.70 | 32.21 | 26.05 | 24.58 | 19.32 | 19.16 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying RMD stock.
ResMed Inc.'s current P/E is 21.8x. The average P/E over the last 4 quarters is 24.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
ResMed Inc.'s current operating margin is 32.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ResMed Inc.'s business trajectory between earnings reports.